Every Form 4 that NovoCure Limited (NVCR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NVCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NVCR filings page.
NovoCure Ltd reported that its Chief Human Resources Officer, Michal Nath Puri, acquired additional equity through an employee share plan. On June 30, 2026, Puri received 1,905 ordinary shares under the 2025 Employee Share Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026. The shares were purchased at $11.15 per share, a price determined as 85% of the closing price of NovoCure’s ordinary shares on January 1, 2026, as provided by the plan. Following this transaction, Puri directly holds 203,227 ordinary shares of NovoCure. The filing notes that this ESPP transaction is exempt under Rule 16b-3(c), reflecting a routine, compensation-related share acquisition rather than an open-market trade.
NovoCure Ltd’s Chief Executive Officer Leonard Frank X acquired 1,905 ordinary shares through the company’s 2025 Employee Share Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026. The shares were purchased at $11.15 per share, based on 85% of the closing price on January 1, 2026. Following this ESPP acquisition, he directly holds 461,425 ordinary shares. The transaction is described as exempt under Rule 16b-3(c).
NovoCure Ltd General Counsel Ben Arye Barak acquired 1,299 ordinary shares through the company’s 2025 Employee Share Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026. The shares were purchased at 85% of the January 1, 2026 closing price, at a reported price of $11.15 per share, bringing his direct holdings to 243,752 shares.
NovoCure Ltd director Asaf Danziger acquired 268 ordinary shares through the company’s 2025 Employee Share Purchase Plan (ESPP). The shares were purchased for $11.15 per share for the ESPP purchase period from January 1, 2026 through June 30, 2026.
Under the ESPP, the purchase price was set at 85% of the closing price of NovoCure’s ordinary shares on January 1, 2026, making this a routine compensation-related acquisition rather than an open-market trade. Following this transaction, Danziger directly owns 416,742 ordinary shares.
NovoCure Ltd Chief Executive Officer Leonard Frank X reported a tax-related sale of 34,273 Ordinary Shares. The shares were sold in open-market transactions at a weighted average price of $17.9335 per share to cover tax withholding obligations arising from the vesting of Restricted Stock Units. According to the company’s equity incentive plan, this “sell to cover” transaction was mandated by the award agreement and is described as not representing a discretionary trade by the CEO. After these sales, Leonard Frank X directly holds 459,520 Ordinary Shares.
NovoCure Ltd director Gabriel Leung received new equity awards as part of compensation. He was granted 11,610 Ordinary Shares in the form of restricted stock units at no cost, increasing his direct holdings to 101,109 Ordinary Shares.
He also received stock options for 16,999 Ordinary Shares at an exercise price of $16.15 per share, expiring on June 3, 2036. Both the restricted stock units and the options are scheduled to vest 100% on the earlier of the first anniversary of the June 3, 2026 grant date or the day immediately preceding NovoCure's 2027 annual general meeting of shareholders.
NovoCure Ltd director Kristin Stafford received new equity awards. She was granted 11,610 ordinary shares in the form of restricted stock units at no cash cost, increasing her direct holdings to 22,934 ordinary shares.
She also received stock options for 16,999 ordinary shares at an exercise price of $16.15 per share. According to the award terms, the restricted stock units are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure's 2027 annual general meeting of shareholders. The options are scheduled to vest and become fully exercisable on the same timetable.
NovoCure Ltd director Allyson J. Ocean received new equity awards. She was granted 11,610 restricted stock units that will vest 100% on the earlier of the first anniversary of the grant or the day immediately preceding the company’s 2027 annual general meeting of shareholders.
She also received stock options for 16,999 ordinary shares at an exercise price of $16.15 per share, which will fully vest on the same schedule and expire on June 3, 2036. Following the restricted stock unit grant, she directly holds 22,934 ordinary shares.
NovoCure Ltd director Timothy J. Scannell received new equity awards as part of his compensation. On June 3, 2026, he was granted 11,610 restricted stock units and stock options for 16,999 ordinary shares at an exercise price of $16.15 per share.
The restricted stock units and options are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure’s 2027 annual general meeting of shareholders. After the restricted stock unit grant, Scannell directly holds 25,898 ordinary shares.
NovoCure Ltd director Jeryl L. Hilleman received new equity awards. On June 3, 2026, she was granted 11,610 Ordinary Shares as restricted stock units and 16,999 stock options with a $16.15 exercise price.
The restricted stock units are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure’s 2027 annual general meeting of shareholders. The stock options follow the same vesting schedule and will become fully exercisable at that time. After the share grant, Hilleman directly holds 25,471 Ordinary Shares, and the option grant represents her reported derivative position in this filing.
NovoCure Ltd director David Hung reported receiving equity awards on ordinary shares. He was granted 11,610 restricted stock units, bringing his direct holdings to 32,075 ordinary shares after the award. He also received options for 16,999 ordinary shares at an exercise price of $16.1500 per share. The restricted stock units are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure’s 2027 annual general meeting of shareholders. The options are scheduled to fully vest and become exercisable on the same timetable, and will expire on June 3, 2036 if not exercised.
NovoCure Ltd director Martin J. Madden received new equity awards as part of his compensation. He was granted 11,610 ordinary shares in the form of restricted stock units, which are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure's 2027 annual general meeting of shareholders.
He was also granted stock options covering 16,999 ordinary shares at an exercise price of $16.15 per share, expiring in 2036. These options will fully vest and become exercisable on the same schedule as the restricted stock units. Following the share grant, Madden directly holds 30,284 ordinary shares.
NovoCure Ltd director Vernon W. Anthony reported equity compensation awards. He received 11,610 ordinary shares in the form of restricted stock units that vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding the company’s 2027 annual general meeting of shareholders. He also received stock options for 16,999 ordinary shares at an exercise price of $16.15 per share, which will fully vest and become exercisable on the same schedule and expire on June 3, 2036. Following these awards, he holds 209,267 ordinary shares directly.
NovoCure Ltd director Gabriel Leung reported a mandatory sale of 2,945 Ordinary Shares to cover taxes on vested Restricted Stock Units. The shares were sold on an open-market basis at a weighted average price of $15.7707 per share. According to the company’s equity incentive plan, this “sell to cover” transaction was required to satisfy tax withholding obligations and was not a discretionary trade by Leung. After the sale, he directly holds 89,499 NovoCure Ordinary Shares.
NovoCure Ltd director Kristin Stafford reported a mandated sale of 2,945 Ordinary Shares. The shares were sold on June 2, 2026 at a weighted average price of $15.7707 per share to cover tax withholding obligations tied to vesting Restricted Stock Units.
The company’s equity incentive plan requires these tax payments to be funded through a “sell to cover” transaction, so this was not a discretionary trade. After the sale, Stafford directly holds 11,324 Ordinary Shares. The transaction was executed in multiple trades between $15.65 and $15.88 per share.
NovoCure Ltd director Allyson J. Ocean reported a mandated sale of ordinary shares linked to equity compensation. On June 2, 2026, she sold 2,945 ordinary shares at a weighted average price of $15.7707 per share.
According to the disclosure, the shares were sold solely to cover tax withholding obligations from the vesting of Restricted Stock Units under NovoCure’s equity incentive plans and did not represent a discretionary trade. Following this transaction, she directly holds 11,324 ordinary shares of NovoCure.
NovoCure Ltd director Timothy J. Scannell reported an open-market sale of 2,945 Ordinary Shares on June 2, 2026 at a weighted average price of $15.7707 per share. According to the disclosure, these shares were sold to cover tax withholding obligations triggered by the vesting of Restricted Stock Units under NovoCure’s equity incentive plans, and the transaction was mandated by a “sell to cover” provision rather than being a discretionary trade. After this sale, Scannell directly holds 14,288 Ordinary Shares of NovoCure.
NovoCure Ltd director Jeryl L. Hilleman reported a mandated sale of 2,945 ordinary shares. The shares were sold on June 2, 2026 at a weighted average price of $15.7707 per share.
According to the disclosure, the sale was required to cover tax withholding obligations tied to the vesting of Restricted Stock Units under NovoCure’s equity incentive plans and did not represent a discretionary trade. After this transaction, Hilleman directly holds 13,861 ordinary shares of NovoCure.
NovoCure Ltd director Vernon W. Anthony reported an open-market sale of 2,945 Ordinary Shares of NovoCure on June 2, 2026 at a weighted average price of $15.7707 per share. According to the footnotes, these shares were sold to cover tax withholding obligations tied to the vesting of Restricted Stock Units under the company’s equity incentive plans and did not represent a discretionary trade. After this transaction, Anthony directly holds 197,657 Ordinary Shares, indicating the sale was a small, routine adjustment for tax purposes rather than a significant change in his overall position.
NovoCure Ltd director David Hung reported a mandated share sale tied to equity compensation. On June 2, 2026, he disposed of 2,945 Ordinary Shares at a weighted average price of $15.7707 per share.
According to the disclosure, these shares were sold solely to cover tax withholding obligations from vesting Restricted Stock Units under the company’s equity incentive plans, and the transaction "does not represent a discretionary trade". After the sale, Hung directly held 20,465 Ordinary Shares. The sale was executed in multiple trades between $15.65 and $15.88 per share.
NovoCure Ltd director Vernon W. Anthony exercised stock options to acquire 21,500 Ordinary Shares at $11.39 per share. These were option exercises rather than open-market purchases or sales. After the transactions, he directly holds 200,602 Ordinary Shares, and the exercised option grant for 21,500 shares has been fully used.
NovoCure Ltd former Chief Medical Officer Nicolas Leupin reported an open-market sale of 1,100 Ordinary Shares on March 4, 2026 at a weighted average price of $13.3054 per share. According to the disclosure, this sale was required to cover tax withholding obligations from vesting Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade. Following this transaction, Leupin directly held 102,979 Ordinary Shares.
NovoCure Ltd reported that former Chief Executive Officer Ashley Cordova had 17,638 ordinary shares withheld on March 4, 2026 to cover tax obligations tied to vesting Restricted Stock Units. The shares were withheld by the issuer at $13.30 per share in a non-discretionary, tax-withholding disposition. After this transaction, Cordova directly owned 422,570 ordinary shares.
NovoCure Ltd reported that its General Counsel, Ben Arye Barak, received new equity awards. He was granted stock options for 73,340 ordinary shares at an exercise price of $0.00 per share, bringing his total options reported in this line to 73,340.
He also acquired 50,125 ordinary shares in the form of restricted share units at $0.00 per share, increasing his directly held ordinary shares to 242,453. The restricted share units are scheduled to vest in three equal annual installments on the first, second and third anniversaries of the grant date, subject to his continued employment. The options are scheduled to vest in four equal annual installments on the first, second, third and fourth anniversaries of the grant date, also subject to continued employment.
NovoCure Ltd chief medical and innovation officer Uri Weinberg reported several equity transactions. He sold 6,412 ordinary shares at a weighted average price of $13.3054 per share to cover tax withholding tied to restricted stock unit vesting, a sale mandated by the company’s equity plan. Following this sale, he held 267,190 ordinary shares. Weinberg also received 50,125 ordinary shares as a grant of restricted share units and 73,340 stock options, both at a grant price of $0.00. The restricted share units are scheduled to vest in three equal parts on the first, second, and third anniversaries of the grant date, while the stock options vest in four equal parts on the first through fourth anniversaries, each subject to his continued employment.
NovoCure Ltd Chief Financial Officer Christoph Brackmann reported a mix of equity grants and a small mandated share sale. He received 55,137 ordinary shares as a restricted stock award, which are scheduled to vest in equal parts on the first, second and third anniversaries of the grant date, subject to continued employment.
He was also granted options over 80,674 ordinary shares, vesting in equal parts on the first through fourth anniversaries, subject to continued employment. In connection with restricted stock unit vesting, he sold 6,412 ordinary shares at a weighted average price of $13.3054 per share to cover tax withholding obligations under a mandatory “sell to cover” arrangement, leaving 182,842 ordinary shares held directly afterward.
NovoCure Ltd Chief Executive Officer Leonard Frank X reported a mix of equity awards and a small share sale. He received a grant of 150,000 ordinary shares in the form of restricted share units that vest in three equal parts on the first, second and third anniversaries of the grant date, subject to continued employment. He also received stock options for 216,388 ordinary shares that vest in four equal parts on the first through fourth anniversaries of the grant date, also subject to continued employment. To cover tax withholding obligations from restricted stock unit vesting, he sold 5,607 ordinary shares in a mandated “sell to cover” transaction at a weighted average price of $13.3054 per share, executed in multiple trades between $13.21 and $13.445. Following these transactions, he directly holds 493,793 ordinary shares and 216,388 stock options.
NovoCure Ltd Chief Operating Officer Paravasthu Mukund reported a combination of equity grants and share sales. On March 3, 2026, he received 45,112 Ordinary Shares as a grant, described as restricted share units that vest in equal parts on the first, second and third anniversaries of the grant date, subject to continued employment. On the same date, he was granted stock options over 7,518 Ordinary Shares and 58,488 Ordinary Shares, with these options scheduled to vest in equal parts on the first, second, third and fourth anniversaries of the grant date, also conditioned on continued employment.
Subsequently, Mukund executed open-market sales of 5,377 Ordinary Shares on March 4, 2026 at a weighted average price of $13.3054 per share and 43,246 Ordinary Shares on March 5, 2026 at a weighted average price of $13.7740 per share. A footnote states that the number of shares sold was required to cover tax withholding obligations related to the vesting of restricted stock units and was mandated by NovoCure's award agreement as a "sell to cover" transaction, rather than a discretionary trade. After the March 5 sale, Mukund directly held 72,832 Ordinary Shares.
NovoCure Ltd's Chief Human Resources Officer, Michal Nath Puri, reported equity compensation and a related tax sale. On March 3, 2026, he received 40,100 ordinary shares as restricted share units that vest over three years and 58,672 stock options vesting over four years. On March 4, 2026, he sold 1,100 ordinary shares at a weighted average price of $13.3054 in a mandated “sell to cover” transaction to satisfy tax withholding, and held 201,322 ordinary shares directly afterward.
NovoCure Ltd Executive Chairman William F. Doyle reported multiple equity compensation transactions on March 3, 2026. He received stock options for 258,445 shares and an additional option grant for 30,072 shares, which are scheduled to vest in equal parts over four years, subject to continued employment.
On the same date, he acquired 200,000 ordinary shares from restricted share units that vest over three years and 200,284 ordinary shares from performance-based restricted stock units that vested. He then sold 50,557 and 21,330 ordinary shares at weighted average prices of $12.7865 and $13.4288 to cover tax withholding obligations under a mandatory “sell to cover” provision, leaving 328,397 ordinary shares held directly.
NovoCure Ltd Chief Medical and Innovation Officer Uri Weinberg reported a mix of share grants and mandated sales. On February 28, he acquired 12,992 ordinary shares at $0.00 per share from vesting of performance-based restricted stock units. Around these vestings, a total of 10,733 shares were sold in open-market transactions on February 27 and March 2 at weighted average prices of about $13.84 and $13.33 per share to cover tax withholding obligations under NovoCure’s equity plans, described as non-discretionary “sell to cover” trades. After these transactions, Weinberg directly owned 223,477 ordinary shares.
NovoCure Ltd’s Chief Human Resources Officer, Michal Nath Puri, reported an automatic sale of 1,441 Ordinary Shares. The shares were sold on February 27, 2026 in open-market trades at a weighted average price of about $13.66 per share, within a range of $13.45 to $13.97.
According to the filing, this was a mandatory “sell to cover” transaction to satisfy tax withholding obligations tied to the vesting of Restricted Stock Units, not a discretionary trade. After this sale, Puri directly held 162,322 Ordinary Shares of NovoCure.
NovoCure Ltd Chief Operating Officer Paravasthu Mukund reported mandated tax-related share sales. He sold a total of 1,963 ordinary shares in open-market transactions, including 1,555 shares on February 27, 2026 at a weighted average price of $13.6638 and 408 shares on March 2, 2026 at a weighted average price of $13.4930.
The filing notes these shares were sold to cover tax withholding obligations arising from vesting of Restricted Stock Units under NovoCure’s equity incentive plans, and the sales were required by a “sell to cover” arrangement rather than being discretionary trades. After these transactions, Mukund directly owns 76,343 ordinary shares.
NovoCure Ltd insider Nicolas Leupin, the company’s former Chief Medical Officer, reported an open-market sale of 1,029 ordinary shares on February 27, 2026 at a weighted average price of $13.6638 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units under NovoCure’s equity incentive plans, as required by the award agreement. After this tax-related, non-discretionary “sell to cover” transaction, Leupin continued to hold 104,079 ordinary shares directly.
NovoCure Ltd’s Chief Executive Officer Leonard Frank X reported a mix of share awards and sales. On February 28, 2026, performance-based restricted stock units vested into 18,621 ordinary shares at no cost to him. Around this vesting, he executed open-market sales totaling 16,966 ordinary shares on February 27 and March 2, 2026 at weighted average prices of about $13.66 and $13.49 per share. A footnote explains that these sales were mandated "sell to cover" transactions to satisfy tax withholding obligations under the company’s equity plans, rather than discretionary trades. Following these transactions, he directly holds 349,400 ordinary shares of NovoCure.
NovoCure Ltd’s former Chief Executive Officer Ashley Cordova reported a mix of equity award activity and related tax withholding. On February 28, 2026, Cordova acquired 23,818 Ordinary Shares at $0.00 per share from the vesting of performance-based restricted stock units.
On February 27 and March 2, 2026, Cordova disposed of Ordinary Shares in several tax-withholding dispositions tied to restricted stock unit vesting. These non-discretionary transactions withheld 11,541 shares at $13.75, and 2,410 and 7,228 shares at $13.67, to cover tax obligations as approved under Rules 16b-3(e) and 16b-3(d)(1).
NovoCure Ltd reported an insider equity award for its General Counsel, Ben Arye Barak. He acquired 17,755 ordinary shares on February 28, 2026 at a stated price of $0.00 per share, described as the vesting of performance-based restricted stock units.
Following this grant/vesting, Barak’s direct holdings increased to 192,328 ordinary shares. This transaction reflects stock-based compensation rather than an open-market purchase or sale.
NovoCure Ltd’s Chief Operating Officer, Paravasthu Mukund, reported an automatic share withholding related to equity compensation. On 01/11/2026, 2,133 ordinary shares were withheld by the company at a price of $14.35 per share to cover tax obligations arising from the vesting of Restricted Stock Units.
After this non-discretionary tax-withholding transaction, Mukund beneficially owns 78,306 ordinary shares directly. The withholding was approved as required under Rules 16b-3(e) and 16b-3(d)(1), and reflects routine tax handling of vested stock-based awards rather than an open-market sale.
NovoCure Ltd. (NVCR) reported an insider transaction on Form 4 for its Chief Financial Officer. On 11/04/2025, 7,033 ordinary shares were withheld at $12.23 to satisfy tax obligations from the vesting of Restricted Stock Units. Following this withholding (transaction code F), the CFO directly holds 134,117 shares. The filing notes the action was not discretionary and was approved pursuant to Rules 16b-3(e) and 16b-3(d)(1).
NovoCure Ltd. (NVCR) reported insider activity by Chief Operating Officer Mukund Paravasthu related to RSU vesting tax withholding. On 11/01/2025, the issuer withheld 168 ordinary shares at $12.81 per share. On 11/04/2025, the issuer withheld an additional 2,949 ordinary shares at $12.23 per share. These are coded “F” transactions, reflecting shares withheld to satisfy tax obligations and described as non-discretionary. Following these transactions, Paravasthu directly beneficially owned 80,439 ordinary shares.
NovoCure Ltd (NVCR) reported an insider transaction on a Form 4. The company’s officer, EVP, President, Novocure Oncology, had 966 ordinary shares withheld on 11/01/2025 at $12.81 per share to satisfy tax obligations upon the vesting of Restricted Stock Units (transaction code F).
Following this non-discretionary withholding, the officer beneficially owns 347,745 shares, held directly. The filing indicates it was made by one reporting person.
NovoCure Ltd (NVCR): The company’s Chief Human Resources Officer reported a tax withholding transaction tied to RSU vesting. On 10/31/2025, 752 ordinary shares were withheld under Transaction Code F at $12.82 per share to satisfy withholding obligations. Following the transaction, the officer beneficially owns 163,762 shares, held directly. The filing notes the action was non‑discretionary and approved pursuant to Rules 16b‑3(e) and 16b‑3(d)(1).